Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis
13 août 2024 08h00 HE
|
Biomed Valley Discoveries, Inc.
Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.
Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
25 févr. 2020 16h03 HE
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company preparing to initiate a...
Kura Oncology Announces Transition of Chief Medical Officer
23 janv. 2020 16h05 HE
|
Kura Oncology, Inc.
– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and medical affairs veteran...
Kura Oncology to Present at J.P. Morgan Healthcare Conference
09 janv. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
06 janv. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Present at Stifel Healthcare Conference
12 nov. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
06 nov. 2019 09h06 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
05 nov. 2019 16h05 HE
|
Kura Oncology, Inc.
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted...
Kura Oncology to Participate in Two Upcoming Investor Conferences
29 août 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
12 août 2019 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...